MedTrace Logo

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

NCT01741844 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2016-04-04

No results posted yet for this study

Summary

The purpose of this study is to assess the safety data of etravirine in a natural clinical practice.

Conditions

  • Acquired Immune Deficiency Syndrome

Interventions

DRUG

No intervention

This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd., Korea Clinical Trial · Janssen Korea, Ltd., Korea

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741844 on ClinicalTrials.gov